MINNEAPOLIS--(BUSINESS WIRE)--CVRx, Inc., a private medical device company, has completed a fourth round of private equity financing totaling $65 million. The company has developed the Rheos™ Baroreflex Hypertension Therapy™ System, the only implantable device designed to control hypertension, a leading cause of heart and kidney disease, stroke and death. Johnson & Johnson Development Corporation was the lead investor. In conjunction with the financing, Dr. Brad Vale, vice president, Johnson & Johnson Development Corporation joined the CVRx Board of Directors.
